---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010176"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:46:32.459567+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma Q2 revenue $48.5M (+29% seq), net loss $(48.0M); advances setmelanotide filings for AHO

## Summary
- Q2 net product revenue $48.5M, up 29% sequentially from Q1 2025; US revenue $32.0M (66% of total), up 31%.
- Net loss $(48.0)M ($(0.75)/share) vs $(33.6)M ($(0.55)/share) in Q2 2024.
- Cash $291M at June 30; added ~$189.2M from July stock offering; paid $40M to LG Chem for bivamelagon.
- Phase 3 TRANSCEND: setmelanotide achieved placebo-adjusted BMI reduction of -19.8% in acquired hypothalamic obesity (AHO).
- Regulatory submissions for setmelanotide in AHO to FDA and EMA on track for Q3 2025; FY 2025 Non-GAAP OpEx guidance $285-315M.

## SEC filing metadata
- accession: 0001558370-25-010176
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000155837025010176/0001558370-25-010176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000155837025010176/rytm-20250805x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010176
- JSON: https://secwatch.observer/filing/0001558370-25-010176.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010176.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.